Geography transfer
EU uptake inherits too much of the US adoption curve without enough adjustment for access, launch sequence, and specialist concentration.
Synthetic sample, no client data
Sample Review: a $1B life-sciences acquisition.
This is how I’d frame the conclusion when a multi-product, multi-geography commercial forecast is directionally plausible but not yet safe to rely on.
Executive conclusion
Repair before reliance.
The acquisition case is not rejected. But leadership should not rely on the current commercial forecast until three decision-changing assumptions are rebuilt and the downside case is driven by causes rather than a proportional cut.
Field-force ramp
The model assumes new commercial capacity becomes productive faster than hiring, training, territory design, and account development can support.
Portfolio interaction
Three product lines are forecast independently, even though shared access, field time, account overlap, and competitive response constrain them together.
Downside logic
The downside case lowers the outputs without changing the drivers that would actually produce a weaker commercial world.
Where the decision would flip
Illustrative thresholds from the synthetic case.
Thresholds turn a forecast into something leadership can monitor. Each one names the condition, why it matters, and what to watch.
EU reimbursement timing
If reimbursement in the major EU markets lands more than 12 months later than plan, the deal no longer clears the hurdle rate at the proposed price.
Watch: early access decisions and launch sequencing in the first two markets.Time to territory productivity
If new territories need more than three quarters to reach target productivity, year-three revenue falls below the range the board approved.
Watch: hiring pace, ramp curves, and account penetration in the first cohort of territories.Early competitive entry
If a second competitor launches before year two, the portfolio case depends on one product holding share it has not yet earned in any market.
Watch: competitor regulatory milestones and early formulary positioning.Decision package
What leadership would receive.
Driver map
Products, geographies, demand, access, field capacity, price, timing, and competition.
Evidence register
Which assumptions are supported, judgmental, inherited, or unresolved.
Independent cases
Reconstructed base, delay, access, competitive, and capacity scenarios.
Decision thresholds
The values or combinations that materially change the acquisition economics.
Action register
What must be repaired before reliance, and who owns each evidence gap.
Reversal criteria
Post-close evidence that should change leadership’s confidence or action.
This sample is synthetic. It shows the structure and analytical standard of a Review. It does not describe any specific client engagement.
Next step
Want this level of clarity on your own forecast?
Send me a few non-confidential sentences about the decision and when it lands. I’ll reply personally with an honest read on whether I can help, and the smallest scope that would.